Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TROV

Cardiff Oncology (TROV) Stock Price, News & Analysis

Cardiff Oncology logo

About Cardiff Oncology Stock (NASDAQ:TROV)

Advanced Chart

Key Stats

Today's Range
$3.84
$4.19
50-Day Range
$1.19
$24.71
52-Week Range
$0.70
$3.46
Volume
1.66 million shs
Average Volume
648,892 shs
Market Capitalization
$43.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TROV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

TROV Stock News Headlines

HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
Cardiff Oncology announces second patent for onvansertib combination
See More Headlines

TROV Stock Analysis - Frequently Asked Questions

Cardiff Oncology, Inc. (NASDAQ:TROV) issued its quarterly earnings results on Thursday, February, 27th. The medical research company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.14. The medical research company had revenue of $0.09 million for the quarter. Cardiff Oncology had a negative net margin of 3,688.31% and a negative trailing twelve-month return on equity of 202.00%.

Shares of Cardiff Oncology reverse split before market open on Wednesday, February 20th 2019.The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include XOMA Royalty (XOMA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Bristol Myers Squibb (BMY), OPKO Health (OPK), Alnylam Pharmaceuticals (ALNY) and VBI Vaccines (VBIV).

Company Calendar

Last Earnings
2/27/2020
Today
7/25/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TROV
CIK
1213037
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$16.41 million
Net Margins
-3,688.31%
Pretax Margin
N/A
Return on Equity
-202.00%
Return on Assets
-122.92%

Debt

Debt-to-Equity Ratio
0.12
Current Ratio
2.37
Quick Ratio
2.37

Sales & Book Value

Annual Sales
$250 thousand
Price / Sales
182.34
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.94 per share
Price / Book
4.40

Miscellaneous

Outstanding Shares
11,011,000
Free Float
N/A
Market Cap
$45.59 million
Optionable
Not Optionable
Beta
1.04
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:TROV) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners